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Hypercalcemia complicating cancers are common in adults,
but are seen very infrequently in children (Tsunematsu et al.,
2000). It occurs in 5% of ovarian malignancies, with small cell and
clear cell carcinoma being the commonest ovarian tumors associat-
ed with hypercalcemia and historically carries a poor prognosis
(Martinez-Borges et al., 2009; McDonald et al., 2012). Juvenile granulosa
cell tumors (JGCTs) of ovary are rare neoplasms that typically occur
in children and young women (Bouffet et al., 1997; Calaminus et al.,
1997). Themajority of childrenwith this tumor are frequently character-
ized by hormonal symptoms like sexual precocity or presentwith signs of
abdominal distension, and/or a palpable pelvic tumor. The majority of
JGCTs are in FIGO (International Federation ofGynecology andObstetrics)
stage I and have a less aggressive behavior than that of adult type
(Calaminus et al., 1997). It has a favorable prognosis when treated
with surgery alone while advanced FIGO stages of this tumor entity are
frequently associated with early relapses. Two cases of ovarian JGCT⁎ Corresponding author at: Department of Pediatric Surgery, Caen University Hospital,
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(Piura et al., 2008; Daubenton and Sinclair-Smith, 2000). The histologi-
cal features and the differential diagnosis of the ovarian cancer with
hypercalcemia in children are discussed.
Case presentation
A 15-year-old white girl was admitted with abdominal pain and
vomiting for 2 days. Two days prior, she was seen by her primary phy-
sician for vomiting. She was prescribed intravenous metoclopramide
without improvement. She was referred to the pediatric emergency
unit for appendicitis suspicion. The girl was febrile with a body tempera-
ture of 38 °C. On physical examination, signs of pubertywere appropriate
for her age (she hadmenarche at age 14). Amass thatwas painful on pal-
pation was located in the right lower quadrant. Headache was reported
without alterations in level of consciousness, or other neurologic symp-
toms. Her vital signs were signiﬁcant with respiratory rate of 24 breaths
per minute, oxygen saturation of 96%, heart rate of 120 beats per min in-
dicating tachycardia, and blood pressure of 136/85 mm Hg. Laboratory
examination showed normal urea and creatinine, but corrected serum
calcium was 14.9 mg/dl (3.70 mmol/l), phosphorus 0.50 mmol/l, LDH
348 U/l, and C-reactive protein level 259 mg/l. Serum parathyroid
hormone-intact (PTH-i) level was 10 pg/ml (normal 10–65). Alpha feto-
protein and beta human chorionic gonadotropin were both normal at
b10 IU/ml. Serum CA-125 was 204 (normal, 0–35)U/ml, while serum
CA-15-3was normal. Serum inhibinwas not ever checked. Electrocardio-
graph was normal. Abdominal ultrasonography demonstrated semisol-
id pelvic mass measuring 125 mm×105 mm×65 mm. An abdominal
contrast-enhanced computed tomography scan revealed a right ovarian
masswithpelvic ascites,without involvement of pelvic structures (Fig. 1).
She was referred to intensive care unit for an antihypercalcemic treat-
ment. Isotonic saline hydration was started together with intravenous
infusion of pamidronate (1 mg/kg) and furosemide. An isotopic (99
mTc-HMDP-“Osteocis”) bone scanning did not detect bone metastasis.
On the six day after starting the management of hypercalcemia, she
underwent a median infraumbilical laparotomy with right salpingo-
oophorectomy, omentectomy and drainage of ascites. Her serum calcium
remained normal.
The tumor measured 120 mm×90 mm×65 mm with soft consis-
tency. Its external surface was smooth and intact. The cut surface was
heterogeneous, showing bright yellow nodular areas alternating with.
Fig. 1. Enhanced pelvis scan shows semisolid pelvic mass.
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fallopian tube and the omentum were normal.
Microscopic examination revealed a solid nodular proliferation of
medium-sized cellswith hypocellular edematous areas, tumor cell necro-
sis and somepseudofollicular structures. The tumor cells hadmoderate to
large amounts of pale or eosinophilic cytoplasm with focal features of
luteinization. The nuclei were round to oval without groove. The cells
were mitotically active, averaging 7 mitoses per 10 high power ﬁelds
(Fig. 3A). Immunohistochemical proﬁle was the following: the tumor
cells demonstrated positive reactivity for alpha-inhibin (Fig. 3B) which
conﬁrms the histological suspicion of a sex-cord stromal process. The
tumor also expressed reactivity to calretinin, estrogen and progesterone
receptors, CD56 and smooth muscle actin. The cells were focally positive
for cytokeratin KL1. The tumorwas negative for TTF1, synaptophysin and
chromogranin, pS100, EMA, and CD99.
These morphological and immunohistochemical features were
the ones of a juvenile granulosa cell tumor, excluding the hypotheses
of a neuroendocrine carcinoma or a clear cell carcinoma of the ovary
which are however the most common ovarian tumors associated
with hypercalcemia.
Discussion
Granulosa cell tumor (GCT) of the ovary is divided into adult and
juvenile types. JGCTs predominantly occur in the ﬁrst three decades ofFig. 3. B: Immunohistochemical staining for alpha-inhibin, showing strong cytoplasmic
immunoreactivity (×400).life and differ from adult granulosa cell tumors with regard to clinical
and pathological features. A common symptom is abdominal pain as-
sociated with palpable mass. JGCTs in infants have been reported in
association with hormonal secretion like sexual precocity, or recent-
ly a reported case with tuberous sclerosis. Calaminus et al. showed
that abdominal distension with a palpable mass was the ﬁrst sign
of the disease reported in sixteen of 33 girls and signs of pseudo-
precocious puberty for fourteen patients at the time of diagnosis
(Calaminus et al., 1997).
Hypercalcemia complicating cancers (JGCTs) of ovary are exceedingly
rare. To our knowledge,wepresent only the third case but the secondone
in children, with Daubenton et al. reporting a case of a girl treated by sur-
gery and chemotherapy and died of the disease 4 months later (Table 1).
Hypercalcemia is exceedingly rare in children. Clear cell adenocarci-
noma of the ovary has been recognized as one of the most common
histologic subtypes associated with hypercalcemia in adult malignan-
cies (Martinez-Borges et al., 2009). In children, dysgerminoma of the
ovary is the second most common ovarian malignancy after ovarian
small cell carcinoma to be associated with hypercalcemia that is due to
production of parathyroid hormone-related protein (PTH-rp) by the
tumor (Piura et al., 2008). In our case, parathyroid hormone level was
normal but like Daubenton et al. we did not have an assay for PTH-rp. Be-
cause hypercalcemia did not recur after removal of the tumor, we think
that it was induced by PTH-rp which was secreted by the tumor.
Abdominal computed tomographic scan shows a large enhanced
abdominopelvic solid mass that can sometimes be a solid and cystic
mass. Piura et al. described a pelvic solid mass with moderate amount
of ascites. Daubenton et al. described a solid and cystic mass in ultraso-
nography. Radiologic characteristics of JGCT are nonspeciﬁc and this
tumor cannot be reliably distinguished from other ovarian neoplasms.
Surgery is the primary option for treatment of localized JGCTs. Stage
IA has a favorable prognosis with a 3-year survival rate of 97% when
treated with conservative surgery alone (unilateral oophorectomy)
(Calaminus et al., 1997). In view of the excellent prognosis of stage IA
JGCT, as it was in our case, additional chemotherapy was not proposed.
Surgery and additional chemotherapy are proposed inmore advanced
stages (stages IC and more) because the recurrence rate is higher
(Calaminus et al., 1997). Stage is the most important prognostic factor
in adult literature. Daubenton et al. reported an 11-year-old black girl
treated with right oophorectomy, omentectomy and chemotherapy. The
histologic diagnosis was a malignant juvenile granulosa cell tumor stage
III and she died of progressive intraabdominal disease 4 months later.
Piura et al. reported a 25-year-old treated with salpingo-oophorectomy
and partial infra-colic omentectomy. Because of the ruptured ovarian
capsule and presence of tumor cells in the ascites, the tumor was allocat-
ed as stage IC and chemotherapywas done. Tenmonths after the surgery
and 7 months after completion of chemotherapy, the patient was alive
and well and without evidence of recurrent disease.
FOXL2 is one of the markers of ovarian differentiation and is re-
quired for the normal development of granulosa cells. This gene belongs
to the large family of forkhead FOX transcription factors. Shah et al.
identiﬁed a recurring somatic mutation in FOXL2: this mutation is de-
scribed in nearly all adult GCT and is thus a speciﬁc marker of this diag-
nosis (Shah et al., 2009). In our case, we did not ﬁnd FOXL2mutation in
the tumor, conﬁrming that it is not an adult GCT. Kalfa et al. showed that
FOXL2 is not expressed or is underexpressed in JGCTwith an aggressive
pattern of progression and it may be a prognostic factor for these tu-
mors (Kalfa et al., 2007). These ﬁndings differ radically from those
reported by D'Angelo et al. who found that patients with JGCT and
higher FOXL2 expression had a worse disease-free survival and overall
survival (D'Angelo et al., 2011). The prognostic signiﬁcance of expres-
sion levels of FOXL2 is so far a controversial subject.
In our case, the patient's serum calcium levels were followed-up
every 3–4 months, which were normal. There had been no recurrence
of the symptoms, and there was normal ultrasonography 24 months
after the surgery.
Table 1
Patients' characteristics.
Age (years) Symptoms Surgical approach Stage (FIGO) CT Outcome
Daubenton 11 Abdominal pain and abdominal mass Salpingo-oophorectomy III Yes Died of the disease
Piura 25 Vomiting and abdominal mass Salpingo-oophorectomy and partial infra-colic omentectomy IC Yes Remission (10 months)
Rod 15 Fever, vomiting and abdominal mass Salpingo-oophorectomy and omentectomy IA No Remission (24 months)
CT: Chemotherapy.
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so that clinicians as well as pathologists are made aware of the rare
paraneoplastic syndrome association of this tumor.Conﬂict of interest statement
None.Appendix A. Supplementary data
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.gynor.2013.02.003.References
Bouffet, E., Basset, T., Chetail, N., Dijoud, F., Mollard, P., Brunat-Mentigny, M., David, M.,
1997. Juvenile granulosa cell tumor of the ovary in infants: a clinicopathologic
study of three cases and review of the literature. J. Pediatr. Surg. 32 (5), 762–765
(May).Calaminus, G., Wessalowski, R., Harms, D., Göbel, U., 1997. Juvenile granulosa cell tumors of
the ovary in children and adolescents: results from 33 patients registered in a prospec-
tive cooperative study. Gynecol. Oncol. 65 (3), 447–452 (Jun).
D'Angelo, E., Mozos, A., Nakayama, D., Espinosa, I., Catasus, L., Munoz, J., Prat, J., 2011. Prog-
nostic signiﬁcance of FOXL2 mutation and mRNA expression in adult and juvenile
granulosa cell tumors of the ovary. Mod. Pathol. 24 (10), 1360–1367 (Oct).
Daubenton, J.D., Sinclair-Smith, C., 2000. Severe hypercalcemia in associationwith a juvenile
granulosa cell tumor of the ovary. Med. Pediatr. Oncol. 34 (4), 301–303 (Apr).
Kalfa, N., Philibert, P., Patte, C., Ecochard, A., Duvillard, P., Baldet, P., Jaubert, F., Fellous,
M., Sultan, C., 2007. Extinction of FOXL2 expression in aggressive ovarian granulosa
cell tumors in children. Fertil. Steril. 87 (4), 896–901 (Apr).
Martinez-Borges, A.R., Petty, J.K., Hurt, G., Stribling, J.T., Press, J.Z., Castellino, S.M., 2009.
Familial small cell carcinoma of the ovary. Pediatr. Blood Cancer 53 (7), 1334–1336
(Dec 15).
McDonald, J.M., Karabakhtsian, R.G., Pierce, H.H., Iocono, J.A., Desimone, C.P., Bayliff,
S.L., Ueland, F.R., 2012. Small cell carcinoma of the ovary of hypercalcemic type:
a case report. J. Pediatr. Surg. 47 (3), 588–592 (Mar).
Piura, B., Wiznitzer, A., Shaco-Levy, R., 2008. Juvenile granulosa cell tumor of the ovary
associated with hypercalcemia. Arch. Gynecol. Obstet. 277 (3), 257–262 (Mar).
Shah, S.P., Köbel, M., Senz, J., Morin, R.D., Clarke, B.A., Huntsman, D.G., et al., 2009.
Mutation of FOXL2 in granulosa-cell tumors of the ovary. N. Engl. J. Med. 360
(26), 2719–2729 (Jun 25).
Tsunematsu, R., Saito, T., Iguchi, H., Fukuda, T., Tsukamoto, N., 2000. Hypercalcemia
due to parathyroid hormone-related protein produced by primary ovarian
clear cell adenocarcinoma: case report. Gynecol. Oncol. 76 (2), 218–222 (Feb).
